{"contentid": 487960, "importid": NaN, "name": "Challenger set to upset Novo Nordisk's dominance in GLP-1 class", "introduction": "Shares in diabetes giant Novo Nordisk fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study.", "content": "<p>Shares in diabetes giant Novo Nordisk (NOV: N) fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study.</p>\n<p>US rival Eli Lilly (NYSE: LLY) reported results from the SURPASS trial program, comparing a range of doses of its GLP-1 receptor agonist tirzepatide with a 1mg dose of semaglutide.</p>\n<p>In the study, Lilly&rsquo;s option led to superior A1C and body weight reductions from baseline across all three doses, for adults with type 2 diabetes.</p>\n<p>The data add to a picture that has been built up over recent months, with a series of late-stage readouts showing significant blood sugar and weight reductions for people taking tirzepatide.</p>\n<p>They will also add to the competitive pressure on Novo Nordisk, which relied on its Ozempic franchise for 11.23 billion Danish kroner ($1.6 billion) in revenues last year.</p>\n<h2>SURPASS-2</h2>\n<p>Importantly, while the higher two doses resulted in double the rate of discontinuations due to adverse events - 8% compared to semaglutide&rsquo;s 4% - the lower, 5mg dose of tirzepatide was almost as well tolerated.</p>\n<p>This dose led to higher weight loss - 7.6kg versus 5.7kg - and higher A1c reduction - 2.01% versus 1.86% - compared with Novo&rsquo;s option.</p>\n<p>Across all treatment arms, the most commonly reported adverse events were gastrointestinal-related.</p>\n<p>Principal investigator Juan Pablo Fr&iacute;as said: \"Head-to-head studies are the gold standard for clinicians assessing the efficacy of investigational treatments, and these results show that all three doses of tirzepatide delivered superior A1C and weight reductions compared to the highest approved dose of semaglutide to treat type 2 diabetes.\"</p>\n<p>He added: \"Newer treatment options may help people with type 2 diabetes achieve their A1C and weight loss goals. In SURPASS-2, tirzepatide delivered clinically-meaningful efficacy, beyond what has been seen with an existing medicine in the established GLP-1 receptor agonist class.\"</p>", "date": "2021-03-05 14:14:00", "meta_title": NaN, "meta_keywords": "diabetes, Novo, GLP-, semaglutide, tirzepatide, weight, study, Nordisk, type, Ozempic, head-to-head, class, doses, dose, agonist, receptor, upset, treatmen", "meta_description": "Shares in diabetes giant Novo Nordisk fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-05 13:54:10", "updated": "2021-03-05 14:16:43", "access": NaN, "url": "https://www.thepharmaletter.com/article/challenger-set-to-upset-novo-s-dominance-in-glp-1-class", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "eli_lilly_science_large.jpg", "image2id": "eli_lilly_science_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Diabetes", "topic_tag": "Drug Trial, Research", "geography_tag": "Denmark, USA", "company_tag": "Eli Lilly, Novo Nordisk", "drug_tag": "Ozempic, semaglutide, tirzepatide", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-05 14:14:00"}